A Fundamental Problem The opioid crisis has spread like an epidemic across North America. Between January 2016 and March 2019, an estimated 12,800 Canadians died from apparent opioid-related overdoses…
PILL.C
Sector Summary The medical sector is a doozy. From cancer to cardiovascular diseases, areas of high unmet medical need are appearing faster than they can be dealt with. According…
Levitee Labs (LVT.C) and Canntab Therapeutics (PILL.C) announced today they are teaming up via a services agreement to go to war with the opioid epidemic, which seems to have…
Long time readers have been aware that, for some time, Equity.Guru has been a supporter of Canntab Therapeutics (PILL.C), but have been frustrated watching the company being slow on…
Business Overview Canntab Therapeutics is a Canadian biopharmaceutical company focused on the manufacturing and distribution of a suite of hard pill cannabinoid formulations in multiple doses and timed-release combinations….
Welcome to Equity.Guru’s Roundtable where our writers weigh in on the pros and cons of a spotlight company, break out where they see value, and help you avoid public…
Canntab Therapeutics (PILL.CN) is a Canadian biopharmaceutical company focused on the manufacturing and distribution of a suite of hard pill cannabinoid formulations in multiple doses and timed-release combinations. Canntab’s…
Canntab Therapeutics (PILL.C) has been around the block and then some. The Ontario-based pharmaceutical answer to medicinal cannabis, has pioneered a patented process to turn CBD, THC and terpene…
Canntab Therapeutics (PILL.C) announced today that it has reached an agreement with 36Eight Technologies (“36Eight”), whereby “36Eight” will list, market, and support all of Canntab’s market-exclusive and patent-protected solid…
Canntab Therapeutics (PILL.C) has received approval for an export license from Health Canada. “We are delighted to have received Health Canada’s export approval to enable us to meet our…